コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 when SHV-1 beta-lactamase is inactivated by clavulanate.
2 r-resistant S130G variant beta-lactamases by clavulanate.
3 ch elude mechanism-based inhibitors, such as clavulanate.
4 ollowed by a 3-wk course of oral amoxicillin/clavulanate.
5 us mezlocillin, ticarcillin, and ticarcillin-clavulanate.
6 quent when testing ampicillin or amoxicillin-clavulanate.
7 etain the carbons of the oxazolidine ring of clavulanate.
8 ly treated with further cycle of amoxicillin/clavulanate.
9 in, ximelagatran, lapatinib, and amoxicillin-clavulanate.
10 noperative management (NOM) with amoxicillin/clavulanate.
11 only -Arg conferred resistance to ampicillin/clavulanate.
12 moniae , results in resistance to ampicillin/clavulanate.
13 illin-sulbactam, amoxicillin, or amoxicillin-clavulanate.
14 mmon among children who received amoxicillin-clavulanate.
15 with a fixed concentration of 4 microg/ml of clavulanate.
16 8-fold increased resistance to the inhibitor clavulanate.
17 important difference compared to ampicillin/clavulanate.
18 amase inhibitors: sulbactam, tazobactam, and clavulanate.
19 t commonly implicated drugs were amoxicillin-clavulanate (21 of 96; 22%), diclofenac (6%), azathiopri
20 Among the children who received amoxicillin-clavulanate, 35% had initial resolution of symptoms by d
21 ed in testing staphylococci with amoxicillin-clavulanate (5 of 127 isolates, 3.9%), pseudomonas with
22 ients were randomized to receive amoxicillin/clavulanate 500/125 mg three times a day or placebo thre
23 icrog/ml versus 4 microg/ml; and ticarcillin-clavulanate, 512 microg/ml versus 16 microg/ml, respecti
24 t, we observed a 5-fold increase in K(i) for clavulanate (7.4 +/- 0.9 microM for Asn276Asp vs 1.4 +/-
25 A total of 117 patients with amoxicillin/clavulanate (74.1%) and 91 with placebo (59.9%) were con
26 lities of amoxicillin (16 micrograms/ml) and clavulanate (8 micrograms/ml), alone and in combination
27 am [3.0/0.375 g q6 hours] +/- PO amoxicillin-clavulanate [800 mg/114 mg q12 hours]), each for 5 to 14
28 a-lactamases confer resistance to ampicillin/clavulanate, a beta-lactam/beta-lactamase inhibitor comb
29 he carbapenem class, such as meropenem, with clavulanate, a beta-lactamase inhibitor, are being evalu
35 patotoxicity caused by isoniazid, phenytoin, clavulanate/amoxicillin, or valproate occurring since 19
37 cluding high-dose amoxicillin or amoxicillin-clavulanate and 3 injections of ceftriaxone; 3 had recur
38 most notable exceptions include ticarcillin-clavulanate and ampicillin, both of which enrich for a l
39 range of beta-lactams (including amoxicillin-clavulanate and cefotaxime) were isolated from scouring
40 In contrast to beta-lactam-based inhibitors clavulanate and cefoxitin, compound 10 did not up-regula
44 urinol and HLA-B*58:01, and both amoxicillin-clavulanate and nevirapine with multiple class I and II
45 chemically inert species, with SHV-1, while clavulanate and sulbactam form a mixture of trans-enamin
48 tam, aztreonam, ticarcillin, and ticarcillin-clavulanate and with P. aeruginosa versus mezlocillin, t
49 S130Gbeta-lactamases (+/- inactivation with clavulanate) and identified peptides modified at the act
50 istered antibiotics, ampicillin, amoxicillin/clavulanate, and ciprofloxacin exhibited marked in vitro
52 and clarithromycin, quinolones, amoxicillin-clavulanate, and second- and third-generation cephalospo
54 cefotaxime (91) alone or in combination with clavulanate; and the standard disk diffusion method with
55 s that meropenem, cefotaxime and ticarcillin-clavulanate are associated with significantly reduced sp
58 Overall 35,252 patients received amoxicillin-clavulanate as outpatients, and DILI occurred in 1 of 23
59 gerus, an industrially important producer of clavulanate as well as cephem antibiotics, also produces
60 lues were 20%, 41%, and 67% with amoxicillin-clavulanate, as compared with 14%, 36%, and 53% with pla
61 allographic structure of BlaC inhibited with clavulanate at a resolution of 1.7 A with an R-factor va
66 azobactam, ampicillin-sulbactam, ticarcillin-clavulanate, cefotaxime, cefotetan, ceftriaxone, cefoxit
67 al agents: amikacin, ampicillin, amoxicillin-clavulanate, ceftriaxone, ciprofloxacin, erythromycin, i
70 d the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for wome
71 d the use of erythromycin and/or amoxicillin-clavulanate (co-amoxiclav) with that of placebo for wome
72 because of off-scale MICs that exceeded the clavulanate combination concentrations in the panel), th
74 illin-tazobactam, meropenem, and ticarcillin-clavulanate conducted in 5 intensive care units across A
75 and R-free value of 0.212 for the m/ z +154 clavulanate-derived fragment observed in the active site
76 confirmatory results were observed for both clavulanate disk augmentation (9/19) and BD Phoenix (5/1
79 rd IV piperacillin-tazobactam/PO amoxicillin-clavulanate dosed multiple times daily for the treatment
82 th acute otitis media to receive amoxicillin-clavulanate either for a standard duration of 10 days or
83 susceptibility were observed for amoxicillin/clavulanate, erythromycin, and levofloxacin among S. pne
84 E. coli clinical isolates were subjected to clavulanate ESBL confirmatory testing employing disk aug
85 up," or adding one-half the concentration of clavulanate every second day, in order to allow accurate
86 namine and imine in the E166A variant, while clavulanate exists almost exclusively as trans-enamine i
88 Soaking of the crystals with ampicillin or clavulanate, followed by flash-freezing, has been carrie
89 ute otitis media, treatment with amoxicillin-clavulanate for 10 days tended to reduce the time to res
90 Children who were treated with amoxicillin-clavulanate for 5 days were more likely than those who w
91 EM-84 (N276D), the water molecule activating clavulanate for cross-linking (Wat1614) is disordered (i
94 edium was 6.7 days, whereas the half-life of clavulanate in combination with amoxicillin was 2.0 days
95 (trihydrate and sodium) in combination with clavulanate in nonradiolabelled 7H12B medium was 6.7 day
96 the half-lives of amoxicillin trihydrate and clavulanate in radiolabelled 7H12B medium were comparabl
98 ase inhibitor combinations (e.g. amoxicillin/clavulanate) in the treatment of serious bacterial infec
100 Electrospray ionization mass spectrometry of clavulanate inhibited SHV-1 and R244S showed nearly iden
101 Proteolytic digestions of purified forms of clavulanate inhibited TEM-2 beta-lactamase followed by a
102 electrospray ionization mass spectrometry of clavulanate-inhibited SHV-1 and SHV Asn276Asp showed nea
103 studies implied that no long-lived forms of clavulanate-inhibited TEM-2 beta-lactamase retain the ca
104 own that amoxicillin-clavulanate can provide clavulanate inhibition of ESBLs and protect an oral ceph
105 testing could detect favorable cephalosporin-clavulanate interactions among a group of 101 previously
106 ns of mild-to-moderate COPD with amoxicillin/clavulanate is more effective and significantly prolongs
109 combination of a beta-lactam antibiotic and clavulanate may lead to rapid bactericidal activity.
110 day, in order to allow accurate amoxicillin-clavulanate MIC testing with the BACTEC mycobacterial su
111 strated reduced susceptibility to ampicillin/clavulanate (MIC increased from 50/2 --> 50/8 microg/mL)
112 remained very active, including amoxicillin-clavulanate (MIC90s, < or =0.25 microg/ml), azithromycin
113 ) or avoid mechanism-based inhibitors (e.g., clavulanate), mutant serine beta-lactamases have not yet
114 The implicated agents included amoxicillin/clavulanate (n = 3), temozolomide (n = 3), various herba
115 ired three twofold-dilution differences with clavulanate needed to confirm an ESBL primarily in the r
116 ed to receive either 40 mg/kg of amoxicillin-clavulanate or a placebo mixture per day for 7 days.
119 An oral fluoroquinolone plus amoxicillin/clavulanate (or plus clindamycin if penicillin allergic)
120 nced on piperacillin-tazobactam, ticarcillin-clavulanate, or meropenem were randomized to receive the
121 s combined with the beta-lactamase inhibitor clavulanate, potent activity against laboratory strains
123 amases revealed that the main determinant of clavulanate resistance was reduced inhibitor affinity.
125 es tested that were resistant to amoxicillin-clavulanate (resistance breakpoint >/= 16/8 mug/ml), 7/7
126 ed for this study as quinolones, amoxicillin/clavulanate, second- and third-generation cephalosporins
127 HV-1 and S130Gbeta-lactamases inactivated by clavulanate showed that the formation of reaction interm
128 populations with ceftazidime and amoxicillin-clavulanate susceptibilities that differed among the cli
129 n eardrops (76 children) or oral amoxicillin-clavulanate suspension (77) or to undergo initial observ
130 among the children treated with amoxicillin-clavulanate than among those who received placebo: 4% ve
131 er for the children treated with amoxicillin-clavulanate than for those who received placebo (P=0.02)
132 osis (Mtb) with the beta-lactamase inhibitor clavulanate together with meropenem resulted in rapid, p
138 nsusceptibility to cefoxitin and amoxicillin-clavulanate was less specific than APBA testing; it iden
143 A beta-lactamases that confer resistance to clavulanate, we performed site-saturation mutagenesis of
146 A mechanistic scheme for the reaction of clavulanate with TEM-2 beta-lactamase is proposed in whi
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。